ArticleClinical case reports2025
A Five-Year Journey to Diagnosis: Resolving Persistent Hypoglycemia Through Successful Insulinoma Resection-A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulinoma is a rare functional pancreatic neuroendocrine tumor with an annual prevalence of 0.5-5 cases per million. It is characterized by excessive insulin secretion, leading to recurrent hypoglycemia, often diagnosed through Whipple's triad: hypoglycemic symptoms, documented low plasma glucose, and symptom resolution after glucose administration. Approximately 90% of insulinomas are sporadic, while 10% are associated with multiple endocrine neoplasia type 1. Diagnosis is frequently delayed due to nonspecific symptoms and misattributions to neurological or psychiatric conditions. Biochemical confirmation through a supervised fasting test and advanced imaging modalities, including CT, MRI, and endoscopic ultrasound (EUS), is essential for identifying and localizing the tumor. We report the case of a 52-year-old male who presented with a 5-year history of recurrent fasting and postprandial hypoglycemic episodes, including adrenergic and neuroglycopenic symptoms such as palpitations, diaphoresis, dizziness, and episodes of altered sensorium. Initial evaluations misattributed his symptoms to neurological and cardiac disorders, delaying diagnosis. Upon presentation, Whipple's triad was confirmed, and biochemical testing revealed hyperinsulinemic hypoglycemia (plasma glucose: 27 mg/dL, serum insulin: 45.83 mIU/L, C-peptide: 7.03 ng/mL). Imaging identified a 3 × 3 cm hypervascular lesion in the pancreatic tail. The patient underwent distal pancreatectomy, and histopathological analysis confirmed a grade 1 neuroendocrine tumor. Postoperative outcomes were favorable, with complete resolution of symptoms and normalization of glucose and insulin levels. Follow-up showed no recurrence of hypoglycemia. This case underscores the challenges in diagnosing insulinoma due to nonspecific symptoms and highlights the importance of Whipple's triad, biochemical tests, and imaging in timely diagnosis. Surgical resection remains the definitive treatment, with excellent long-term outcomes when performed promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.